Global Chemotherapy Induced Anemia Market is segmented By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia), By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Research Centers, Cancer Rehabilitation Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Chemotherapy Induced Anemia Market Size
The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2031. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2024-2031). Chemotherapy-induced anemia (CIA) is an outcome of the malignant incursion of regular tissues inducing blood loss, bone marrow incursion with disturbance of erythropoiesis, and functioning iron depletion outcome of inflammation.
CIA is a considerable effect of chemotherapy and may slow or restrict therapy and contribute to both diminished quality of life and fatigue. Alas, not all medical professionals invariably monitor, estimate, or consistently record anemia-related manifestations.
Chemotherapy Induced Anemia Market Scope
|
Metrics |
Details |
|
CAGR |
7.2% |
|
Size Available for Years |
2022−2031 |
|
Forecast Period |
2024−2031 |
|
Data Availability |
Value (USD) |
|
Segments Covered |
Disease Type, Treatment Type, Drug Type, End User, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Disease Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis key Insights. |
For more insights - Request Free Sample
Chemotherapy Induced Anemia Market Dynamics
The Increasing Research Activities Are Driving The Global Chemotherapy-Induced Anemia Market Growth In The Forecast Period.
The increasing research activities for treatment options for chemotherapy-induced anemia are driving the global chemotherapy-induced anemia market during the forecast period. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical corporation dedicated to uncovering, designing, and marketing a pipeline of first-in-class therapeutics, and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. reported positive topline data from Company’s Phase 3 clinical investigation of roxadustat for therapy of anemia in individuals accepting simultaneous chemotherapy medicine for non-myeloid malignancies in China.
The Presence Of Stringent Regulatory Policies Hampers The Global Chemotherapy-Induced Anemia Market Growth.
The presence of stringent regulatory authority bodies approving the usage and commercialization of drugs or biologics employed in the treatment of chemotherapy-induced anemia is hampering the global chemotherapy-induced anemia market growth during the forecast period. For instance, the European Medicines Agency (EMA), an agency of the European Union in command of the evaluation and surveillance of pharmaceutical developments, and the US Food and Drug Administration (USFDA), a nationwide agency of the Department of Health and Human Services are prominent regulatory authoritative bodies among others.
Chemotherapy Induced Anemia Market Segment Analysis
The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.
The RBC Transfusions Treatment Type Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.
The RBC transfusions treatment type segment is estimated to dominate the global market holding around 38.2% of the total market share owing to the increasing research development in this segment. For instance, in November 2022, researchers conducted the foremost transfusions of RBCs developed in a lab as an element of a U.K.-based clinical investigation to experiment with how prolonged these cells can survive. The group raised blood from stem cells that they had isolated from donated blood. When positioned in a nutrient solution, the stem cells can mature into any type of cell in the body, and reproduce, and the investigators enticed them to turn into RBCs.
Source: DataM Intelligence Analysis (2023)
Chemotherapy Induced Anemia Market Geographical Share
North America Holds The Largest Share Of The Global Chemotherapy-Induced Anemia Market.
North America is estimated to hold around 38.7% of the global chemotherapy-induced anemia market owing to the increasing cancer cases and growing cancer research funding in this region. For instance, established on American Cancer Society data for 2023, there are around 1,958,310 new cancer cases and 609,820 cancer deaths anticipated to be in the United States.
Moreover, as part of a longstanding collaboration, the Bren Simon Comprehensive Cancer Center and Indiana University Melvin have obtained fresh and continued grants from the American Cancer Society to sustain research and schooling schedules. IU cancer investigators are presently accepting over USD 6 million in multi-year ACS grants across the Bloomington and Indianapolis campuses.
Source: DataM Intelligence Analysis (2023)
Chemotherapy Induced Anemia Companies
The major global players in the market include Dr. Reddy’s Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.
Russia-Ukraine War Impact Analysis
As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.
Key Developments
- In October 2022, Pfizer Inc., an American multinational pharmaceutical and biotechnology company, reported positive outcomes from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an orally administered poly ADP-ribose polymerase (PARP) inhibitor, in blend with XTANDI (enzalutamide), indicating a statistically substantial and clinically significant progress in radiographic progression-free survival (rPFS) than placebo plus XTANDI in males with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.
- In February 2023, the U.S. Food and Drug Administration (FDA) awarded Priority Review for Pfizer’s TALZENNA in combination with XTANDI for the treatment of men with mCRPC, a supplemental new drug application. The FDA awards Priority Review to drugs that may present substantial betterment in therapy or may deliver a therapy where no satisfactory treatment exists.
Why Purchase the Report?
- To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
